LITTLE FALLS, NJ--(Marketwire - June 07, 2011) - Regenicin, Inc. (OTCBB: RGIN) announces today that Dr. Craig Eagle who sits on the Regenicin Board of Directors, attended The World Stem Cells and Regenerative Medicine Congress 2011 in efforts to further Regencin's push towards obtaining FDA approval for the commercial sale of its first product candidate.
The World Stem Cells and Regenerative Medicine Congress is a senior director-level, interactive conference experience. Speakers and panelists are industry leaders from throughout Europe, North America and Asia. The World Stem Cells and Regenerative Medicine Congress is Europe's most progressive strategic conference where ideas, intelligence and relationships really make a difference.
"The World Stem Cells and Regenerative Medicine Congress plays a vital role in advancing awareness of the most ground-breaking developments in the field, recognizing key industry leaders, and facilitating top level conversations about strategic planning and partnerships," says Randall McCoy, CEO of Regenicin. "It is great to see that Regenicin is perfectly in line with stem cell technology that is being pursued by the rest of the world."
About Regenicin, Inc.
Regenicin, Inc. is a biotechnology company with corporate headquarters in Little Falls, New Jersey. The Company specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitation, the future press releases of Regenicin, Inc.